nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—Haemolysis—Cisplatin—esophageal cancer	0.0294	0.0698	CcSEcCtD
Halofantrine—Tetany—Cisplatin—esophageal cancer	0.0287	0.0681	CcSEcCtD
Halofantrine—Hypertensive crisis—Capecitabine—esophageal cancer	0.0248	0.059	CcSEcCtD
Halofantrine—Altered state of consciousness—Capecitabine—esophageal cancer	0.0149	0.0355	CcSEcCtD
Halofantrine—Haematocrit decreased—Methotrexate—esophageal cancer	0.0138	0.0327	CcSEcCtD
Halofantrine—Platelet count decreased—Capecitabine—esophageal cancer	0.0116	0.0275	CcSEcCtD
Halofantrine—Rigors—Capecitabine—esophageal cancer	0.00843	0.0201	CcSEcCtD
Halofantrine—Haemolytic anaemia—Cisplatin—esophageal cancer	0.00751	0.0179	CcSEcCtD
Halofantrine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00692	0.0165	CcSEcCtD
Halofantrine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00665	0.0158	CcSEcCtD
Halofantrine—Face oedema—Cisplatin—esophageal cancer	0.00655	0.0156	CcSEcCtD
Halofantrine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00619	0.0147	CcSEcCtD
Halofantrine—Abnormal vision—Capecitabine—esophageal cancer	0.00601	0.0143	CcSEcCtD
Halofantrine—Sleep disorder—Capecitabine—esophageal cancer	0.00577	0.0137	CcSEcCtD
Halofantrine—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00554	0.0132	CcSEcCtD
Halofantrine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.0051	0.0121	CcSEcCtD
Halofantrine—Stomatitis—Cisplatin—esophageal cancer	0.00509	0.0121	CcSEcCtD
Halofantrine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00495	0.0118	CcSEcCtD
Halofantrine—Face oedema—Capecitabine—esophageal cancer	0.00483	0.0115	CcSEcCtD
Halofantrine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00457	0.0109	CcSEcCtD
Halofantrine—Pulmonary oedema—Methotrexate—esophageal cancer	0.00456	0.0108	CcSEcCtD
Halofantrine—Visual impairment—Cisplatin—esophageal cancer	0.00452	0.0107	CcSEcCtD
Halofantrine—Tinnitus—Cisplatin—esophageal cancer	0.00437	0.0104	CcSEcCtD
Halofantrine—Abdominal distension—Capecitabine—esophageal cancer	0.00435	0.0103	CcSEcCtD
Halofantrine—Arrhythmia—Cisplatin—esophageal cancer	0.00419	0.00996	CcSEcCtD
Halofantrine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.0038	0.00903	CcSEcCtD
Halofantrine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00379	0.00901	CcSEcCtD
Halofantrine—Stomatitis—Capecitabine—esophageal cancer	0.00375	0.00893	CcSEcCtD
Halofantrine—Malaise—Cisplatin—esophageal cancer	0.00368	0.00876	CcSEcCtD
Halofantrine—Convulsion—Cisplatin—esophageal cancer	0.00354	0.00841	CcSEcCtD
Halofantrine—Myalgia—Cisplatin—esophageal cancer	0.00348	0.00827	CcSEcCtD
Halofantrine—Discomfort—Cisplatin—esophageal cancer	0.00343	0.00817	CcSEcCtD
Halofantrine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00333	0.00792	CcSEcCtD
Halofantrine—Visual impairment—Capecitabine—esophageal cancer	0.00333	0.00792	CcSEcCtD
Halofantrine—Tinnitus—Capecitabine—esophageal cancer	0.00322	0.00767	CcSEcCtD
Halofantrine—Anorexia—Cisplatin—esophageal cancer	0.00318	0.00755	CcSEcCtD
Halofantrine—Chills—Capecitabine—esophageal cancer	0.0031	0.00738	CcSEcCtD
Halofantrine—Arrhythmia—Capecitabine—esophageal cancer	0.00309	0.00734	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00304	0.00722	CcSEcCtD
Halofantrine—Paraesthesia—Cisplatin—esophageal cancer	0.00299	0.00712	CcSEcCtD
Halofantrine—Back pain—Capecitabine—esophageal cancer	0.00291	0.00692	CcSEcCtD
Halofantrine—Decreased appetite—Cisplatin—esophageal cancer	0.0029	0.00689	CcSEcCtD
Halofantrine—Stomatitis—Methotrexate—esophageal cancer	0.00279	0.00665	CcSEcCtD
Halofantrine—Ill-defined disorder—Capecitabine—esophageal cancer	0.00279	0.00664	CcSEcCtD
Halofantrine—Feeling abnormal—Cisplatin—esophageal cancer	0.00275	0.00653	CcSEcCtD
Halofantrine—Malaise—Capecitabine—esophageal cancer	0.00271	0.00645	CcSEcCtD
Halofantrine—Palpitations—Capecitabine—esophageal cancer	0.00266	0.00632	CcSEcCtD
Halofantrine—Cough—Capecitabine—esophageal cancer	0.00263	0.00625	CcSEcCtD
Halofantrine—Arthralgia—Capecitabine—esophageal cancer	0.00256	0.00609	CcSEcCtD
Halofantrine—Chest pain—Capecitabine—esophageal cancer	0.00256	0.00609	CcSEcCtD
Halofantrine—Myalgia—Capecitabine—esophageal cancer	0.00256	0.00609	CcSEcCtD
Halofantrine—Discomfort—Capecitabine—esophageal cancer	0.00253	0.00602	CcSEcCtD
Halofantrine—Visual impairment—Methotrexate—esophageal cancer	0.00248	0.0059	CcSEcCtD
Halofantrine—Confusional state—Capecitabine—esophageal cancer	0.00248	0.00589	CcSEcCtD
Halofantrine—Tinnitus—Methotrexate—esophageal cancer	0.0024	0.00571	CcSEcCtD
Halofantrine—Asthenia—Cisplatin—esophageal cancer	0.00239	0.00569	CcSEcCtD
Halofantrine—Anorexia—Capecitabine—esophageal cancer	0.00234	0.00557	CcSEcCtD
Halofantrine—Chills—Methotrexate—esophageal cancer	0.00231	0.00549	CcSEcCtD
Halofantrine—Diarrhoea—Cisplatin—esophageal cancer	0.00228	0.00542	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00224	0.00532	CcSEcCtD
Halofantrine—Paraesthesia—Capecitabine—esophageal cancer	0.00221	0.00525	CcSEcCtD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.0022	0.00379	CbGpPWpGaD
Halofantrine—Back pain—Methotrexate—esophageal cancer	0.00217	0.00515	CcSEcCtD
Halofantrine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00217	0.00374	CbGpPWpGaD
Halofantrine—Dyspepsia—Capecitabine—esophageal cancer	0.00216	0.00514	CcSEcCtD
Halofantrine—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00214	0.00369	CbGpPWpGaD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00214	0.00369	CbGpPWpGaD
Halofantrine—Decreased appetite—Capecitabine—esophageal cancer	0.00214	0.00508	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—ADH7—esophageal cancer	0.00212	0.00366	CbGpPWpGaD
Halofantrine—Vomiting—Cisplatin—esophageal cancer	0.00212	0.00504	CcSEcCtD
Halofantrine—Fatigue—Capecitabine—esophageal cancer	0.00212	0.00504	CcSEcCtD
Halofantrine—Rash—Cisplatin—esophageal cancer	0.0021	0.005	CcSEcCtD
Halofantrine—KCNH2—Neuronal System—GNG7—esophageal cancer	0.0021	0.00363	CbGpPWpGaD
Halofantrine—Constipation—Capecitabine—esophageal cancer	0.0021	0.005	CcSEcCtD
Halofantrine—Dermatitis—Cisplatin—esophageal cancer	0.0021	0.00499	CcSEcCtD
Halofantrine—Ill-defined disorder—Methotrexate—esophageal cancer	0.00208	0.00494	CcSEcCtD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00203	0.00351	CbGpPWpGaD
Halofantrine—Feeling abnormal—Capecitabine—esophageal cancer	0.00202	0.00481	CcSEcCtD
Halofantrine—Malaise—Methotrexate—esophageal cancer	0.00202	0.0048	CcSEcCtD
Halofantrine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00201	0.00478	CcSEcCtD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00201	0.00347	CbGpPWpGaD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00201	0.00346	CbGpPWpGaD
Halofantrine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.002	0.00345	CbGpPWpGaD
Halofantrine—Nausea—Cisplatin—esophageal cancer	0.00198	0.00471	CcSEcCtD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00197	0.0034	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—ALDH2—esophageal cancer	0.00197	0.0034	CbGpPWpGaD
Halofantrine—Cough—Methotrexate—esophageal cancer	0.00196	0.00465	CcSEcCtD
Halofantrine—Urticaria—Capecitabine—esophageal cancer	0.00195	0.00464	CcSEcCtD
Halofantrine—Abdominal pain—Capecitabine—esophageal cancer	0.00194	0.00462	CcSEcCtD
Halofantrine—Convulsion—Methotrexate—esophageal cancer	0.00194	0.00462	CcSEcCtD
Halofantrine—Chest pain—Methotrexate—esophageal cancer	0.00191	0.00454	CcSEcCtD
Halofantrine—Arthralgia—Methotrexate—esophageal cancer	0.00191	0.00454	CcSEcCtD
Halofantrine—Myalgia—Methotrexate—esophageal cancer	0.00191	0.00454	CcSEcCtD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.0019	0.00329	CbGpPWpGaD
Halofantrine—Discomfort—Methotrexate—esophageal cancer	0.00188	0.00448	CcSEcCtD
Halofantrine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00188	0.00324	CbGpPWpGaD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00187	0.00323	CbGpPWpGaD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00187	0.00322	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—ADH1B—esophageal cancer	0.00186	0.00321	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00186	0.0032	CbGpPWpGaD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00185	0.0032	CbGpPWpGaD
Halofantrine—Confusional state—Methotrexate—esophageal cancer	0.00184	0.00438	CcSEcCtD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00184	0.00318	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—ADH7—esophageal cancer	0.00184	0.00317	CbGpPWpGaD
Halofantrine—Anaphylactic shock—Methotrexate—esophageal cancer	0.00183	0.00435	CcSEcCtD
Halofantrine—Asthenia—Capecitabine—esophageal cancer	0.00176	0.00419	CcSEcCtD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00176	0.00303	CbGpPWpGaD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00175	0.00303	CbGpPWpGaD
Halofantrine—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00175	0.00302	CbGpPWpGaD
Halofantrine—Anorexia—Methotrexate—esophageal cancer	0.00174	0.00414	CcSEcCtD
Halofantrine—Pruritus—Capecitabine—esophageal cancer	0.00174	0.00413	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—CYP26A1—esophageal cancer	0.00173	0.00298	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP26A1—esophageal cancer	0.0017	0.00294	CbGpPWpGaD
Halofantrine—Diarrhoea—Capecitabine—esophageal cancer	0.00168	0.004	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00167	0.00396	CcSEcCtD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00165	0.00285	CbGpPWpGaD
Halofantrine—Paraesthesia—Methotrexate—esophageal cancer	0.00164	0.0039	CcSEcCtD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00164	0.00283	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00163	0.00281	CbGpPWpGaD
Halofantrine—Dizziness—Capecitabine—esophageal cancer	0.00162	0.00386	CcSEcCtD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00162	0.00279	CbGpPWpGaD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00162	0.00279	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—ADH1B—esophageal cancer	0.00161	0.00278	CbGpPWpGaD
Halofantrine—Dyspepsia—Methotrexate—esophageal cancer	0.00161	0.00383	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—GSTO1—esophageal cancer	0.00161	0.00277	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.0016	0.00276	CbGpPWpGaD
Halofantrine—Decreased appetite—Methotrexate—esophageal cancer	0.00159	0.00378	CcSEcCtD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTO1—esophageal cancer	0.00158	0.00274	CbGpPWpGaD
Halofantrine—Fatigue—Methotrexate—esophageal cancer	0.00158	0.00375	CcSEcCtD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00156	0.0027	CbGpPWpGaD
Halofantrine—Vomiting—Capecitabine—esophageal cancer	0.00156	0.00371	CcSEcCtD
Halofantrine—Rash—Capecitabine—esophageal cancer	0.00155	0.00368	CcSEcCtD
Halofantrine—Dermatitis—Capecitabine—esophageal cancer	0.00155	0.00368	CcSEcCtD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00154	0.00266	CbGpPWpGaD
Halofantrine—Headache—Capecitabine—esophageal cancer	0.00154	0.00366	CcSEcCtD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00152	0.00263	CbGpPWpGaD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00152	0.00262	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00151	0.00261	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.00151	0.0026	CbGpPWpGaD
Halofantrine—Feeling abnormal—Methotrexate—esophageal cancer	0.00151	0.00358	CcSEcCtD
Halofantrine—CYP2C8—Biological oxidations—CYP26A1—esophageal cancer	0.0015	0.00258	CbGpPWpGaD
Halofantrine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.0015	0.00356	CcSEcCtD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00148	0.00255	CbGpPWpGaD
Halofantrine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00146	0.00252	CbGpPWpGaD
Halofantrine—Nausea—Capecitabine—esophageal cancer	0.00146	0.00347	CcSEcCtD
Halofantrine—Urticaria—Methotrexate—esophageal cancer	0.00145	0.00345	CcSEcCtD
Halofantrine—Abdominal pain—Methotrexate—esophageal cancer	0.00145	0.00344	CcSEcCtD
Halofantrine—CYP2C8—Biological oxidations—GSTO1—esophageal cancer	0.00139	0.0024	CbGpPWpGaD
Halofantrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00139	0.0024	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTO1—esophageal cancer	0.00137	0.00237	CbGpPWpGaD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00133	0.00229	CbGpPWpGaD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00133	0.00229	CbGpPWpGaD
Halofantrine—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00133	0.00229	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.00132	0.00228	CbGpPWpGaD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00131	0.00226	CbGpPWpGaD
Halofantrine—Asthenia—Methotrexate—esophageal cancer	0.00131	0.00312	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—ALDH2—esophageal cancer	0.00131	0.00226	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.00131	0.00226	CbGpPWpGaD
Halofantrine—Pruritus—Methotrexate—esophageal cancer	0.00129	0.00308	CcSEcCtD
Halofantrine—Diarrhoea—Methotrexate—esophageal cancer	0.00125	0.00298	CcSEcCtD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00125	0.00216	CbGpPWpGaD
Halofantrine—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00125	0.00215	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTT1—esophageal cancer	0.00125	0.00215	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—CYP2A6—esophageal cancer	0.00123	0.00213	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.00123	0.00212	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00121	0.00209	CbGpPWpGaD
Halofantrine—Dizziness—Methotrexate—esophageal cancer	0.00121	0.00288	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—PTGS1—esophageal cancer	0.00117	0.00201	CbGpPWpGaD
Halofantrine—Vomiting—Methotrexate—esophageal cancer	0.00116	0.00276	CcSEcCtD
Halofantrine—Rash—Methotrexate—esophageal cancer	0.00115	0.00274	CcSEcCtD
Halofantrine—Dermatitis—Methotrexate—esophageal cancer	0.00115	0.00274	CcSEcCtD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00115	0.00198	CbGpPWpGaD
Halofantrine—Headache—Methotrexate—esophageal cancer	0.00115	0.00272	CcSEcCtD
Halofantrine—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.00114	0.00197	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—ALDH2—esophageal cancer	0.00113	0.00196	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.00113	0.00194	CbGpPWpGaD
Halofantrine—Nausea—Methotrexate—esophageal cancer	0.00109	0.00258	CcSEcCtD
Halofantrine—CYP2C8—Biological oxidations—GSTT1—esophageal cancer	0.00108	0.00186	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00108	0.00186	CbGpPWpGaD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00107	0.00185	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—CYP2A6—esophageal cancer	0.00107	0.00184	CbGpPWpGaD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00106	0.00183	CbGpPWpGaD
Halofantrine—CYP2C8—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.00104	0.0018	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00102	0.00176	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—PTGS1—esophageal cancer	0.00101	0.00175	CbGpPWpGaD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00101	0.00174	CbGpPWpGaD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000994	0.00172	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—CYP1B1—esophageal cancer	0.000993	0.00171	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000986	0.0017	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000979	0.00169	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—CYP19A1—esophageal cancer	0.000933	0.00161	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000931	0.00161	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000921	0.00159	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.00089	0.00154	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000886	0.00153	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000876	0.00151	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000869	0.0015	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000864	0.00149	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—CYP1B1—esophageal cancer	0.00086	0.00148	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000848	0.00146	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.00083	0.00143	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000829	0.00143	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000817	0.00141	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—CYP19A1—esophageal cancer	0.000808	0.0014	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000804	0.00139	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000797	0.00138	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000793	0.00137	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000747	0.00129	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000737	0.00127	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000706	0.00122	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000696	0.0012	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000664	0.00115	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000655	0.00113	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000609	0.00105	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000579	0.001	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000573	0.000988	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.00056	0.000967	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000543	0.000937	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—SLC52A3—esophageal cancer	0.000502	0.000866	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—BLVRB—esophageal cancer	0.000502	0.000866	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000489	0.000844	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000462	0.000797	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000455	0.000786	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—BLVRB—esophageal cancer	0.000434	0.00075	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—SLC52A3—esophageal cancer	0.000434	0.00075	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000434	0.000749	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000428	0.000739	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—SLC10A2—esophageal cancer	0.000426	0.000736	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CA1—esophageal cancer	0.000426	0.000736	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CA2—esophageal cancer	0.00039	0.000673	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000388	0.00067	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CA1—esophageal cancer	0.000369	0.000637	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—SLC10A2—esophageal cancer	0.000369	0.000637	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ADH7—esophageal cancer	0.000363	0.000626	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PLCE1—esophageal cancer	0.000363	0.000626	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000357	0.000615	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000357	0.000615	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CA2—esophageal cancer	0.000338	0.000583	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.00033	0.00057	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ADH1B—esophageal cancer	0.000318	0.000549	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PLCE1—esophageal cancer	0.000314	0.000542	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ADH7—esophageal cancer	0.000314	0.000542	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.00031	0.000536	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—TYMP—esophageal cancer	0.000304	0.000524	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000303	0.000523	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CA1—esophageal cancer	0.000303	0.000523	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP26A1—esophageal cancer	0.000296	0.00051	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ALOX15—esophageal cancer	0.000288	0.000497	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CA2—esophageal cancer	0.000277	0.000479	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ADH1B—esophageal cancer	0.000275	0.000475	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTO1—esophageal cancer	0.000275	0.000474	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—TPI1—esophageal cancer	0.000275	0.000474	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ALDOB—esophageal cancer	0.000263	0.000455	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—TYMP—esophageal cancer	0.000263	0.000454	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000258	0.000445	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000258	0.000445	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP26A1—esophageal cancer	0.000256	0.000442	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GAPDH—esophageal cancer	0.000254	0.000438	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CRABP1—esophageal cancer	0.000251	0.000434	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ALOX15—esophageal cancer	0.000249	0.000431	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GNG7—esophageal cancer	0.000239	0.000413	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTO1—esophageal cancer	0.000238	0.000411	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—TPI1—esophageal cancer	0.000238	0.000411	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000233	0.000402	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000233	0.000402	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ALDOB—esophageal cancer	0.000228	0.000394	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000226	0.00039	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ALDH2—esophageal cancer	0.000224	0.000387	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GAPDH—esophageal cancer	0.00022	0.000379	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CRABP1—esophageal cancer	0.000218	0.000376	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000216	0.000373	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTT1—esophageal cancer	0.000213	0.000368	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP2A6—esophageal cancer	0.000211	0.000363	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.00021	0.000363	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GNG7—esophageal cancer	0.000207	0.000357	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000205	0.000354	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ENO1—esophageal cancer	0.0002	0.000345	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PTGS1—esophageal cancer	0.0002	0.000345	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000198	0.000342	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CA1—esophageal cancer	0.000198	0.000342	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PSME1—esophageal cancer	0.000197	0.00034	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PSME2—esophageal cancer	0.000197	0.00034	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000195	0.000337	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000195	0.000337	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ALDH2—esophageal cancer	0.000194	0.000335	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000187	0.000323	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTT1—esophageal cancer	0.000185	0.000319	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP2A6—esophageal cancer	0.000182	0.000315	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000182	0.000314	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CA2—esophageal cancer	0.000181	0.000313	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.00018	0.000311	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000179	0.000308	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ENO1—esophageal cancer	0.000173	0.000298	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PTGS1—esophageal cancer	0.000173	0.000298	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PSME1—esophageal cancer	0.00017	0.000294	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PSME2—esophageal cancer	0.00017	0.000294	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GNG7—esophageal cancer	0.00017	0.000293	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP1B1—esophageal cancer	0.00017	0.000293	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000169	0.000291	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000169	0.000291	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP19A1—esophageal cancer	0.00016	0.000275	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000159	0.000275	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000152	0.000261	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.00015	0.000258	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000149	0.000257	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000148	0.000255	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP1B1—esophageal cancer	0.000147	0.000254	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—HMOX1—esophageal cancer	0.000146	0.000251	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000142	0.000245	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000142	0.000245	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000141	0.000244	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PSME1—esophageal cancer	0.00014	0.000241	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PSME2—esophageal cancer	0.00014	0.000241	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ABCB1—esophageal cancer	0.00014	0.000241	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP19A1—esophageal cancer	0.000138	0.000239	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.000137	0.000237	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000134	0.000231	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000128	0.00022	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000128	0.00022	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—HMOX1—esophageal cancer	0.000126	0.000218	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000124	0.000214	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.000122	0.000211	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ABCB1—esophageal cancer	0.000121	0.000209	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000121	0.000208	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GAPDH—esophageal cancer	0.000118	0.000203	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CRABP1—esophageal cancer	0.000117	0.000202	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000114	0.000196	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GNG7—esophageal cancer	0.000111	0.000192	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ALDH2—esophageal cancer	0.000104	0.00018	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—HMOX1—esophageal cancer	0.000104	0.000179	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ABCB1—esophageal cancer	9.94e-05	0.000172	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTT1—esophageal cancer	9.91e-05	0.000171	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	9.79e-05	0.000169	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CREBBP—esophageal cancer	9.34e-05	0.000161	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PTGS1—esophageal cancer	9.28e-05	0.00016	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ENO1—esophageal cancer	9.28e-05	0.00016	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.16e-05	0.000158	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PSME1—esophageal cancer	9.15e-05	0.000158	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PSME2—esophageal cancer	9.15e-05	0.000158	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—NOS3—esophageal cancer	8.37e-05	0.000144	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CREBBP—esophageal cancer	8.09e-05	0.00014	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	7.89e-05	0.000136	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PTGS2—esophageal cancer	7.65e-05	0.000132	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.42e-05	0.000128	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—NOS3—esophageal cancer	7.25e-05	0.000125	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—HMOX1—esophageal cancer	6.77e-05	0.000117	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CREBBP—esophageal cancer	6.64e-05	0.000115	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PTGS2—esophageal cancer	6.63e-05	0.000114	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.5e-05	0.000112	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—EP300—esophageal cancer	6.36e-05	0.00011	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—NOS3—esophageal cancer	5.95e-05	0.000103	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—EP300—esophageal cancer	5.51e-05	9.51e-05	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PTGS2—esophageal cancer	5.44e-05	9.39e-05	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PIK3CA—esophageal cancer	4.71e-05	8.12e-05	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—EP300—esophageal cancer	4.53e-05	7.81e-05	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.34e-05	7.5e-05	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PIK3CA—esophageal cancer	4.08e-05	7.04e-05	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—NOS3—esophageal cancer	3.89e-05	6.71e-05	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.56e-05	6.14e-05	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	3.35e-05	5.78e-05	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—EP300—esophageal cancer	2.96e-05	5.11e-05	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.19e-05	3.78e-05	CbGpPWpGaD
